QRxPharma Limited operates as a clinical-stage specialty pharmaceutical company that focuses on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders in Australia. The company's product portfolio includes both late and early stage clinical drug candidates. It intends to directly commercialize its products in the U.S. and seek strategic partnerships for worldwide markets. Products The company’s preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease, and venomics. The company's primary compound, MoxDuo IR (Q8003IR), is in Phase 3 clinical development and has completed multiple comparative studies evaluating its efficacy and safety against equianalgesic doses of morphine, oxycodone, and Percocet for the treatment of acute pain. The company's Dual-Opioid product portfolio includes two complementary products: MoxDuo CR, a controlled-release oral capsule (with abuse deterrent and tamper resistant technologies) for chronic pain; and MoxDuo IV, an intravenous formulation for treating moderate to severe hospital-based pain. The company intends to initiate a Phase 2 comparative proof-of-concept study evaluating the efficacy and safety of MoxDuo IV (an intravenous morphine plus oxycodone formulation) against IV morphine for the treatment of moderate to severe post-operative pain. It also intends to initiate its Phase 1 study of MoxDuo CR, a continuous release Dual-Opioid. Additionally, the company is advancing the development of its Torsin program under collaborative research agreement with the University of Alabama (Caldwell Labs). These small molecules target dystonia, Parkinson’s disease, and Alzheimer’s disease, as well as similar neurologic disorders. Preclinical trials are underway to evaluate the company’s drug candidates in Parkinson’s disease. Agreements The company has a collaborative research agreement with the University of Queensland for the conduct of the Australian Research Council linkage project grant of ‘pre-clinical evaluation of snake venom proteins with therapeutic potential’.
(QRX:Australian Stock Exchange Ltd)
100 Walker Street
North Sydney, NSW 2060
Phone: 61 2 8404 4139
Fax: 61 2 8920 0314www.qrxpharma.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for QRX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact QRXPHARMA LTD, please visit www.qrxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.